tiprankstipranks
Advertisement
Advertisement

NPCE Stock Latest News

NeuroPace reports Q2 EPS (18c), consensus (20c)
The FlyNeuroPace reports Q2 EPS (18c), consensus (20c)
13d ago
NPCE
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
PremiumThe Fly
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
13d ago
NPCE
NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
PremiumThe Fly
NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
26d ago
NPCE
NeuroPace faces FDA setback on epilepsy label expansion
PremiumCompany Announcements
NeuroPace faces FDA setback on epilepsy label expansion
27d ago
8K
NPCE
NeuroPace initiated with an Outperform at Mizuho
PremiumThe Fly
NeuroPace initiated with an Outperform at Mizuho
1M ago
NPCE
NeuroPace Shareholders Approve Directors and Auditor at Meeting
PremiumCompany AnnouncementsNeuroPace Shareholders Approve Directors and Auditor at Meeting
3M ago
8K
NPCE
NeuroPace announces FDA approval of ECoG Assistant
Premium
The Fly
NeuroPace announces FDA approval of ECoG Assistant
3M ago
NPCE
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
Premium
The Fly
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
3M ago
NPCE
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
PremiumCompany Announcements
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
3M ago
NPCE
NeuroPace Earnings Call Highlights RNS Growth Momentum
PremiumCompany Announcements
NeuroPace Earnings Call Highlights RNS Growth Momentum
3M ago
NPCE
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
PremiumRatings
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
3M ago
NPCE
NeuroPace reports Q1 EPS (20c), consensus (23c)
PremiumThe Fly
NeuroPace reports Q1 EPS (20c), consensus (23c)
3M ago
NPCE
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
PremiumThe FlyNeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
3M ago
NPCE
NeuroPace announces publication of 3-year results from RNS System PAS
Premium
The Fly
NeuroPace announces publication of 3-year results from RNS System PAS
4M ago
NPCE
NeuroPace Earnings Call Highlights Growth And AI Push
Premium
Company Announcements
NeuroPace Earnings Call Highlights Growth And AI Push
5M ago
NPCE
NeuroPace assumed with an Overweight at Wells Fargo
PremiumThe Fly
NeuroPace assumed with an Overweight at Wells Fargo
5M ago
NPCE
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
PremiumRatings
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
6M ago
NPCE
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
PremiumCompany Announcements
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
6M ago
NPCE
NeuroPace reports Q4 EPS (8c), consensus (17c)
PremiumThe Fly
NeuroPace reports Q4 EPS (8c), consensus (17c)
6M ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
PremiumThe FlyNeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
6M ago
NPCE
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
Premium
The Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
6M ago
NPCE
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >